Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Verastem Oncology announced that the FDA has granted Fast Track Designation to VS-7375 for the treatment of KRAS G12D-mutated non-small cell lung cancer (NSCLC). This designation expands the regulatory pathway for VS-7375 beyond its previously granted Fast Track status for pancreatic cancer, targeting a large patient population with limited treatment options.
Key figures
- Drug Name
- VS-7375
- Phase Of Trial
- Phase 2
- Target d 202 dose
- 900 mg once daily
- Nsclc total prevalence
- 80-85%
- Nsclc kras g12d prevalence
- 5%
- Us annual kras g12d diagnoses
- 8,000
- Target d 101 max dose evaluated
- 1200 mg once daily
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.